These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 33336585)

  • 1. Hypoxia-associated alternative splicing signature in lung adenocarcinoma.
    Xu Z; Wei J; Qin F; Sun Y; Xiang W; Yuan L; Qin J; Deng K; Zheng T; Li S
    Epigenomics; 2021 Jan; 13(1):47-63. PubMed ID: 33336585
    [No Abstract]   [Full Text] [Related]  

  • 2. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study.
    Chen G; Dong Z; Wu D; Chen Y
    J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic signature of lung adenocarcinoma based on stem cell-related genes.
    Huang Z; Shi M; Zhou H; Wang J; Zhang HJ; Shi J-
    Sci Rep; 2021 Jan; 11(1):1687. PubMed ID: 33462260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-Wide Analysis of Prognostic Alternative Splicing Signature and Splicing Factors in Lung Adenocarcinoma.
    Chang YS; Tu SJ; Chiang HS; Yen JC; Lee YT; Fang HY; Chang JG
    Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33142748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment and validation of an immune-associated signature in lung adenocarcinoma.
    Wang Z; Chen X
    Int Immunopharmacol; 2020 Nov; 88():106867. PubMed ID: 32799112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel radiomic nomogram for predicting epidermal growth factor receptor mutation in peripheral lung adenocarcinoma.
    Lu X; Li M; Zhang H; Hua S; Meng F; Yang H; Li X; Cao D
    Phys Med Biol; 2020 Mar; 65(5):055012. PubMed ID: 31978901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of a nomogram with an epigenetic signature for predicting survival in patients with lung adenocarcinoma.
    Wang J; He L; Tang Y; Li D; Yang Y; Zeng Z
    Aging (Albany NY); 2020 Nov; 12(22):23200-23216. PubMed ID: 33221751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of an oxidative phosphorylation-related gene signature in lung adenocarcinoma.
    Xu Z; Wu Z; Zhang J; Zhou R; Ye L; Yang P; Yu B
    Epigenomics; 2020 Aug; 12(15):1333-1348. PubMed ID: 32787683
    [No Abstract]   [Full Text] [Related]  

  • 10. Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma.
    Wang H; Wei C; Pan P; Yuan F; Cheng J
    Sci Rep; 2021 May; 11(1):9938. PubMed ID: 33976305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
    Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
    Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of predictive and prognostic alternative splicing signatures in lung adenocarcinoma using machine learning methods.
    Cai Q; He B; Zhang P; Zhao Z; Peng X; Zhang Y; Xie H; Wang X
    J Transl Med; 2020 Dec; 18(1):463. PubMed ID: 33287830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a novel epigenetic-related prognostic signature and candidate drugs for patients with lung adenocarcinoma.
    Wang Z; Embaye KS; Yang Q; Qin L; Zhang C; Liu L; Zhan X; Zhang F; Wang X; Qin S
    Aging (Albany NY); 2021 Jul; 13(14):18701-18717. PubMed ID: 34285141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.
    Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q
    Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of 4 immune cells and a 5-lncRNA risk signature with prognosis for early-stage lung adenocarcinoma.
    Mu L; Ding K; Tu R; Yang W
    J Transl Med; 2021 Mar; 19(1):127. PubMed ID: 33771173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel ferroptosis-related genes model for prognosis prediction of lung adenocarcinoma.
    Li F; Ge D; Sun SL
    BMC Pulm Med; 2021 Jul; 21(1):229. PubMed ID: 34256754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic construction and validation of an epithelial-mesenchymal transition risk model to predict prognosis of lung adenocarcinoma.
    Tang Y; Jiang Y; Qing C; Wang J; Zeng Z
    Aging (Albany NY); 2020 Dec; 13(1):794-812. PubMed ID: 33340396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA methylation profiling to predict recurrence risk in stage Ι lung adenocarcinoma: Development and validation of a nomogram to clinical management.
    Ma X; Cheng J; Zhao P; Li L; Tao K; Chen H
    J Cell Mol Med; 2020 Jul; 24(13):7576-7589. PubMed ID: 32530136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
    Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
    BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An interactive network of alternative splicing events with prognostic value in geriatric lung adenocarcinoma via the regulation of splicing factors.
    Wang Y; Wang Y; Li K; Du Y; Cui K; Yu P; Zhang T; Liu H; Ma W
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33000861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.